Report

Our reports provide latest industry trends, forecasts, company profiles, competitive landscape, and strategic insights.

Asset 41 2
160 1608792 circle document icon png transparent png

Europe Glycomic Therapeutics Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – Class (Isolated and Synthetic), Structures [Glycoproteins, Targeting Sialic Acid, Proteoglycans, Targeting Glycosaminoglycans, Glycosylphosphatidylinositol (GPI)-Anchored Proteins & Heparin Based Glycans, Targeting Glycosphingolipids, and Others], Indications (Thrombosis & Chemoprophylaxis, Anaemia, Anti-Adhesive & Anti-Inflammatory, Cataracts, Gaucher’s Disease, MPS-1 & IV, Cancer, Alzheimer’s Disease, Influenza Type A & B, and Others), Mode of Action [Inhibits Neuraminidase, Inhibits Heparanase and Selectins and Blocks Interactions Between Growth Factors and Heparan Sulfate, Erythropoietin & Enzyme Replacement Therapy (ERT), Tissue Plasminogen Activator, Inhibits Glucosylceramide Synthas Interleukin 1 and 2 and 3, Beta & Gamma Interferons, and Others]

The glycomic therapeutics market in Europe is expected to grow from US$ 37,002.34 million in 2022 to US$ 88,658.62 million by 2028; it is estimated to grow at a CAGR of 14.5% from 2022 to 2028.

Increasing Research and Development in Glycomic Therapeutics Drives Market Growth

Glycans may be exceedingly complex and are found in many areas of the microbiome components, such as proteins and cell surfaces. Researchers and players are actively involved in the glycomics industry and are constantly focusing on technological developments to offer better alternatives to conventional techniques. For instance, in March 2022, Palleon Pharmaceuticals, a company pioneering the field of glycol-immunology to treat cancer and inflammatory diseases, announced the dosing of the first patient in the company’s Phase 1/2 study of E-602 in patients suffering from an advanced stage of cancers. The study, called GLIMMER-01 (Glycan-Immune Regulation), is the first clinical study of Palleon’s novel approach to cancer immunotherapy, which targets immunosuppressive sialoglycans. In April 2022, CPTAC glycoproteomic researchers developed the “Peptide-First” multi-attribute glycan identification method. According to a study published in February 2022 by researchers at the University of Copenhagen’s Center for Glycomics, Heparin can now be produced without using animal through glycomics studies. Such research and developments in the field of glycomics are driving the glycomics therapeutics market growth.

Market Overview

The Europe glycomic therapeutics market is segmented into Germany, the UK, France, Italy, Spain, and the Rest of Europe. The region holds a significant share of the glycomic therapeutics market. Europe occupies a significant position in the glycomic therapeutics market and is estimated to register a robust growth rate over the forecast period. The market growth in the region is expected due to the rising number of cancer cases and viral infection and an increase in investment in research and development.

Europe Glycomic Therapeutics Market Revenue and Forecast to 2028 (US$ Billion)

Europe Glycomic Therapeutics Market Segmentation

The Europe glycomic therapeutics market is segmented on the basis of class, structure, indications, mode of action, and country.

Based on class, the Europe glycomic therapeutics market is bifurcated into isolated and synthetic. The synthetic segment registered a larger market share in 2022. Based on structure, the Europe glycomic therapeutics market is segmented into glycoproteins, targeting sialic acid, proteoglycans, targeting glycosaminoglycans, glycosylphosphatidylinositol (GPI)-anchored proteins & heparin based glycans, targeting glycosphingolipids, and others. The glycoproteins segment held the largest market share in 2022. Based on indications, the Europe glycomic therapeutics market is segmented into thrombosis & chemoprophylaxis, anaemia, anti-adhesive & anti-inflammatory, cataracts, gaucher’s disease, MPS-1 & IV, cancer, alzheimer’s disease, influenza type A & B, and others. The influenza type a & b segment held the largest market share in 2022. Based on mode of action, the Europe glycomic therapeutics market is segmented into inhibits neuraminidase, inhibits heparanase and selectins and blocks interactions between growth factors and heparan sulfate, erythropoietin & enzyme replacement therapy (ERT), tissue plasminogen activator, inhibits glucosylceramide synthase, interleukin 1 and 2 and 3, beta & gamma interferons, and others. The erythropoietin & enzyme replacement therapy (ERT) segment held the largest market share in 2022. Based on country, the Europe glycomic therapeutics market is segmented into the UK, Germany, France, Italy, Spain, and the Rest of Europe. Germany dominated the market in 2022. Intellihep Ltd; BioMarin Pharmaceutical Inc.; Genzyme Corporation(Sanofi); Bayer AG; Alzheon, Inc.; GlycoMar; GlaxoSmithKline plc.; and F. Hoffmann-La Roche Ltd. are the leading companies operating in the glycomic therapeutics in Europe.

TABLE OF CONTENTS

1. Introduction
1.1 Study Scope
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
1.3.1 Europe Glycomic Therapeutics Market – By Class
1.3.2 Europe Glycomic Therapeutics Market – By Structures
1.3.3 Europe Glycomic Therapeutics Market – By Indications
1.3.4 Europe Glycomic Therapeutics Market – By Mode of Action
1.3.5 Europe Glycomic Therapeutics Market – By Country
2. Europe Glycomic Therapeutics Market– Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Europe Glycomic Therapeutics Market – Market Landscape
4.1 Overview
4.2 PEST Analysis
4.2.1 Europe – PEST Analysis
4.3 Expert Opinion
5. Europe Glycomic Therapeutics Market – Key Market Dynamics
5.1 Market Drivers
5.1.1 Wide Application in Various Disorders Followed by the Development of New Treatment Processes
5.1.2 Increasing Research and Development In the Field of Glycomic Therapeutics
5.2 Market Restraints
5.2.1 Shortage of Skilled Professionals and Lack of Research & Development laboratories in Developing Countries.
5.3 Market Opportunities
5.3.1 Wide Applications of Glycomics in Therapeutics
5.4 Future Trends
5.4.1 New Tools in Glycomics Research
5.5 Impact Analysis
6. Glycomic Therapeutics Market– Europe Analysis
6.1 Europe Glycomic Therapeutics Market Revenue Forecast and Analysis
7. Europe Glycomic Therapeutics Market Revenue and Forecast to 2028– by Class
7.1 Overview
7.2 Europe Glycomic Therapeutics Market, By Class 2022 & 2028 (%)
7.2.1 Europe: Glycomic Therapeutics Market, by Class, 2019-2028 (US$ Million)
7.3 Isolated
7.3.1 Overview
7.3.2 Europe Isolated Revenue and Forecast to 2028 (US$ Million)
7.4 Synthetic
7.4.1 Overview
7.4.2 Europe Synthetic – Revenue and Forecast to 2028 (US$ Million)
8. Europe Glycomics Therapeutics Market Analysis and Forecasts To 2028 – By Indication
8.1 Overview
8.2 Europe Glycomics Market, By Indication 2022 & 2028 (%)
8.2.1 Europe: Glycomic Therapeutics Market, by Indication, 2019-2028 (US$ Million)
8.3 Thrombosis and Chemoprophylaxis
8.3.1 Overview
8.3.2 Europe Thrombosis and chemoprophylaxis Revenue and Forecast to 2028 (US$ Million)
8.4 Anaemia
8.4.1 Overview
8.4.2 Europe Anaemia Revenue and Forecast to 2028 (US$ Million)
8.5 Anti-adhesive and Anti-inflammatory
8.5.1 Overview
8.5.2 Europe Anti-adhesive and Anti-inflammatory Revenue and Forecast to 2028 (US$ Million)
8.6 Cataract
8.6.1 Overview
8.6.2 Europe Cataract Revenue and Forecast to 2028 (US$ Million)
8.7 Gaucher’s diseases
8.7.1 Overview
8.7.2 Europe Gaucher’s diseases Revenue and Forecast to 2028 (US$ Million)
8.8 MPS-1 & IV
8.8.1 Overview
8.8.2 Europe MPS-1 & IV Revenue and Forecast to 2028 (US$ Million)
8.9 Cancer
8.9.1 Overview
8.9.2 Europe Cancer Revenue and Forecast to 2028 (US$ Million)
8.10 Alzheimer’s
8.10.1 Overview
8.10.2 Europe Alzheimer’s Revenue and Forecast to 2028 (US$ Million)
8.11 Influenza Type A and B
8.11.1 Overview
8.11.2 Europe Influenza Type A and B Revenue and Forecast to 2028 (US$ Million)
8.12 Others
8.12.1 Overview
8.12.2 Europe Others Revenue and Forecast to 2028 (US$ Million)
9. Europe Glycomic Therapeutics Market Revenue and Forecast to 2028 – by Structures
9.1 Overview
9.2 Europe Glycomic Therapeutics Market, By Structures 2022 & 2028 (%)
9.2.1 Europe: Glycomic Therapeutics Market, by Structure, 2019-2028 (US$ Million)
9.2.1.1 Europe: Glycomic Therapeutics Market, by Targeting Sialic Acid, 2019-2028 (US$ Million)
9.2.1.2 Europe: Glycomic Therapeutics Market, by Targeting Glycosaminoglycan, 2019-2028 (US$ Million)
9.2.1.3 Europe: Glycomic Therapeutics Market, by Targeting Glycosphingolipids, 2019-2028 (US$ Million)
9.2.1.4 Europe: Glycomic Therapeutics Market, by Others, 2019-2028 (US$ Million)
9.3 Glycoproteins
9.3.1 Overview
9.3.2 Europe Glycoproteins – Market Revenue and Forecast to 2028 (US$ Million)
9.4 Targeting Sialic Acid
9.4.1 Overview
9.4.2 Europe Targeting Sialic Acid – Market Revenue and Forecast to 2028 (US$ Million)
9.4.3 Zanamivir
9.4.3.1 Overview
9.4.4 Europe Zanamivir – Market Revenue and Forecast to 2028 (US$ Million)
9.4.5 Oseltamivir
9.4.5.1 Overview
9.4.5.2 Europe Oseltamivir – Market Revenue and Forecast to 2028 (US$ Million)
9.5 Proteoglycans
9.5.1 Overview
9.5.2 Europe Proteoglycans – Market Revenue and Forecast to 2028 (US$ Million)
9.6 Glycosylphosphatidylinositol (GPI)-Anchored Proteins and Heparin Based Glycans
9.6.1 Overview
9.6.2 Europe Glycosylphosphatidylinositol (GPI)-Anchored Proteins and Heparin Based Glycans – Market Revenue and Forecast to 2028 (US$ Million)
9.7 Targeting Glycosaminoglycans
9.7.1 Overview
9.7.2 Europe Targeting Glycosaminoglycans – Market Revenue and Forecast to 2028 (US$ Million)
9.7.3 Heparin
9.7.3.1 Overview
9.7.3.2 Europe Heparin – Market Revenue and Forecast to 2028 (US$ Million)
9.7.4 Hyaluronan (HA)
9.7.4.1 Overview
9.7.4.2 Europe Hyaluronan (HA)- Market Revenue and Forecast to 2028 (US$ Million)
9.7.5 Laronidase
9.7.5.1 Overview
9.7.5.2 Europe Laronidase – Market Revenue and Forecast to 2028 (US$ Million)
9.7.6 Galsulfase (Naglazyme)
9.7.6.1 Overview
9.7.6.2 Europe Galsulfase (Naglazyme) – Market Revenue and Forecast to 2028 (US$ Million)
9.7.7 Hyaluronidase (Cumulase)
9.7.7.1 Overview
9.7.7.2 Europe Hyaluronidase (Cumulase) – Market Revenue and Forecast to 2028 (US$ Million)
9.7.8 Others
9.7.8.1 Overview
9.7.8.2 Europe Others – Market Revenue and Forecast to 2028 (US$ Million)
9.8 Targeting Glycosphingolipids
9.8.1 Overview
9.8.2 Europe Targeting Glycosphingolipids – Market Revenue and Forecast to 2028 (US$ Million)
9.8.3 Imiglucerase (Cerezyme)
9.8.3.1 Overview
9.8.3.2 Europe Imiglucerase (Cerezyme)- Market Revenue and Forecast to 2028 (US$ Million)
9.8.3.3 Agalsidase (Fabrazyme)
9.8.3.3.1 Overview
9.8.3.3.2 Europe Agalsidase (Fabrazyme) – Market Revenue and Forecast to 2028 (US$ Million)
9.8.3.4 N-butyl-deoxynojirimycin (DNJ)
9.8.3.4.1 Overview
9.8.3.5 Europe N-butyl-deoxynojirimycin (DNJ) – Market Revenue and Forecast to 2028 (US$ Million)
9.8.4 Others
9.8.4.1 Overview
9.8.4.2 Europe Others – Market Revenue and Forecast to 2028 (US$ Million)
9.9 Others
9.9.1 Overview
9.9.2 Europe Others – Market Revenue and Forecast to 2028 (US$ Million)
9.9.3 Acarbose
9.9.3.1 Overview
9.9.3.2 Europe Acarbose – Market Revenue and Forecast to 2028 (US$ Million)
9.9.3.3 Alglucosidase Alfa (Myozyme)
9.9.3.3.1 Overview
9.9.3.3.2 Europe Alglucosidase Alfa (Myozyme) – Market Revenue and Forecast to 2028 (US$ Million)
9.9.3.4 Allosamidin
9.9.3.4.1 Overview
9.9.3.4.2 Europe Allosamidin – Market Revenue and Forecast to 2028 (US$ Million)
9.9.4 Others
9.9.4.1 Overview
9.9.4.2 Europe Others – Market Revenue and Forecast to 2028 (US$ Million)
10. Europe Glycomic Therapeutics Market Revenue and Forecast to 2028 – by Mode of Action
10.1 Overview
10.2 Europe Glycomic Therapeutics Market, By Mode of Action 2022 & 2028 (%)
10.2.1 Europe: Glycomic Therapeutics Market, by Mode of Action, 2019-2028 (US$ Million)
10.3 Inhibits Neuraminidase
10.3.1 Overview
10.3.2 Europe Inhibits Neuraminidase – Market Revenue and Forecast to 2028 (US$ Million)
10.4 Inhibits Heparanase And Selectins And Blocks Interactions Between Growth Factors And Heparan Sulfate
10.4.1 Overview
10.4.2 Europe Inhibits Heparanase And Selectins And Blocks Interactions Between Growth Factors And Heparan Sulfate – Market Revenue and Forecast to 2028 (US$ Million)
10.5 Erythropoietin And Enzyme Replacement Therapy (ERT)
10.5.1 Overview
10.5.2 Europe Erythropoietin And Enzyme Replacement Therapy (ERT) – Market Revenue and Forecast to 2028 (US$ Million)
10.6 Tissue Plasminogen Activator
10.6.1 Overview
10.6.2 Europe Tissue Plasminogen Activator – Market Revenue And Forecasts To 2028 (US$ Million)
10.7 Inhibits Glucosylceramide Synthase
10.7.1 Overview
10.7.2 Europe Inhibits Glucosylceramide Synthase – Market Revenue And Forecasts To 2028 (US$ Million)
10.8 Interleukin 1 And 2 And 3
10.8.1 Overview
10.8.2 Europe Interleukin 1 And 2 And 3- Market Revenue And Forecasts To 2028 (US$ Million)
10.9 Beta And Gamma Interferons
10.9.1 Overview
10.9.2 Europe Beta And Gamma Interferons- Market Revenue And Forecasts To 2028 (US$ Million)
10.10 Others
10.10.1 Overview
10.10.2 Europe Others- Market Revenue And Forecasts To 2028 (US$ Million)
11. Europe Glycomic Therapeutics Market Revenue and Forecasts to 2028 – Country Analysis
11.1 Europe: Glycomic Therapeutics Market
11.1.1 Overview
11.1.2 Europe: Glycomic Therapeutics Market, by Class, 2019-2028 (US$ Million)
11.1.3 Europe: Glycomic Therapeutics Market, by Structure, 2019-2028 (US$ Million)
11.1.3.1 Europe: Glycomic Therapeutics Market, by Targeting Sialic Acid, 2019-2028 (US$ Million)
11.1.3.2 Europe: Glycomic Therapeutics Market, by Targeting Glycosaminoglycan, 2019-2028 (US$ Million)
11.1.3.3 Europe: Glycomic Therapeutics Market, by Targeting Glycosphingolipids, 2019-2028 (US$ Million)
11.1.3.4 Europe: Glycomic Therapeutics Market, by Others, 2019-2028 (US$ Million)
11.1.4 Europe: Glycomic Therapeutics Market, by Indication, 2019-2028 (US$ Million)
11.1.5 Europe: Glycomic Therapeutics Market, by Mode of Action, 2019-2028 (US$ Million)
11.1.6 Europe: Glycomic Therapeutics Market, by Country, 2021 & 2028 (%)
11.1.6.1 Germany: Glycomic Therapeutics Market – Revenue and Forecast to 2028 (US$ Million)
11.1.6.1.1 Overview
11.1.6.1.2 Germany: Glycomic Therapeutics Market – Revenue and Forecast to 2028 (US$ Million)
11.1.6.1.3 Germany: Glycomic Therapeutics Market, by Class, 2019-2028 (US$ Million)
11.1.6.1.4 Germany: Glycomic Therapeutics Market, by Structure, 2019-2028 (US$ Million)
11.1.6.1.4.1 Germany: Glycomic Therapeutics Market, by Targeting Sialic Acid, 2019-2028 (US$ Million)
11.1.6.1.4.2 Germany: Glycomic Therapeutics Market, by Targeting Glycosaminoglycan, 2019-2028 (US$ Million)
11.1.6.1.4.3 Germany: Glycomic Therapeutics Market, by Targeting Glycosphingolipids, 2019-2028 (US$ Million)
11.1.6.1.4.4 Germany: Glycomic Therapeutics Market, by Others, 2019-2028 (US$ Million)
11.1.6.1.5 Germany: Glycomic Therapeutics Market, by Indication, 2019-2028 (US$ Million)
11.1.6.1.6 Germany: Glycomic Therapeutics Market, by Mode of Action, 2019-2028 (US$ Million)
11.1.6.2 UK: Glycomic Therapeutics Market – Revenue and Forecast to 2028 (US$ Million)
11.1.6.2.1 Overview
11.1.6.2.2 UK: Glycomic Therapeutics Market – Revenue and Forecast to 2028 (US$ Million)
11.1.6.2.3 UK: Glycomic Therapeutics Market, by Class, 2019-2028 (US$ Million)
11.1.6.2.4 UK: Glycomic Therapeutics Market, by Structure, 2019-2028 (US$ Million)
11.1.6.2.4.1 UK: Glycomic Therapeutics Market, by Targeting Sialic Acid, 2019-2028 (US$ Million)
11.1.6.2.4.2 UK: Glycomic Therapeutics Market, by Targeting Glycosaminoglycan, 2019-2028 (US$ Million)
11.1.6.2.4.3 UK: Glycomic Therapeutics Market, by Targeting Glycosphingolipids, 2019-2028 (US$ Million)
11.1.6.2.4.4 UK: Glycomic Therapeutics Market, by Others, 2019-2028 (US$ Million)
11.1.6.2.5 UK: Glycomic Therapeutics Market, by Indication, 2019-2028 (US$ Million)
11.1.6.2.6 UK: Glycomic Therapeutics Market, by Mode of Action, 2019-2028 (US$ Million)
11.1.6.3 France: Glycomic Therapeutics Market – Revenue and Forecast to 2028 (US$ Million)
11.1.6.3.1 Overview
11.1.6.3.2 France: Glycomic Therapeutics Market – Revenue and Forecast to 2028 (US$ Million)
11.1.6.3.3 France: Glycomic Therapeutics Market, by Class, 2019-2028 (US$ Million)
11.1.6.3.4 France: Glycomic Therapeutics Market, by Structure, 2019-2028 (US$ Million)
11.1.6.3.4.1 France: Glycomic Therapeutics Market, by Targeting Sialic Acid, 2019-2028 (US$ Million)
11.1.6.3.4.2 France: Glycomic Therapeutics Market, by Targeting Glycosaminoglycan, 2019-2028 (US$ Million)
11.1.6.3.4.3 France: Glycomic Therapeutics Market, by Targeting Glycosphingolipids, 2019-2028 (US$ Million)
11.1.6.3.4.4 France: Glycomic Therapeutics Market, by Others, 2019-2028 (US$ Million)
11.1.6.3.5 France: Glycomic Therapeutics Market, by Indication, 2019-2028 (US$ Million)
11.1.6.3.6 France: Glycomic Therapeutics Market, by Mode of Action, 2019-2028 (US$ Million)
11.1.6.4 Italy: Glycomic Therapeutics Market – Revenue and Forecast to 2028 (US$ Million)
11.1.6.4.1 Overview
11.1.6.4.2 Italy: Glycomic Therapeutics Market – Revenue and Forecast to 2028 (US$ Million)
11.1.6.4.3 Italy: Glycomic Therapeutics Market, by Class, 2019-2028 (US$ Million)
11.1.6.4.4 Italy: Glycomic Therapeutics Market, by Structure, 2019-2028 (US$ Million)
11.1.6.4.4.1 Italy: Glycomic Therapeutics Market, by Targeting Sialic Acid, 2019-2028 (US$ Million)
11.1.6.4.4.2 Italy: Glycomic Therapeutics Market, by Targeting Glycosaminoglycan, 2019-2028 (US$ Million)
11.1.6.4.4.3 Italy: Glycomic Therapeutics Market, by Targeting Glycosphingolipids, 2019-2028 (US$ Million)
11.1.6.4.4.4 Italy: Glycomic Therapeutics Market, by Others, 2019-2028 (US$ Million)
11.1.6.4.5 Italy: Glycomic Therapeutics Market, by Indication, 2019-2028 (US$ Million)
11.1.6.4.6 Italy: Glycomic Therapeutics Market, by Mode of Action, 2019-2028 (US$ Million)
11.1.6.5 Spain: Glycomic Therapeutics Market – Revenue and Forecast to 2028 (US$ Million)
11.1.6.5.1 Overview
11.1.6.5.2 Spain: Glycomic Therapeutics Market – Revenue and Forecast to 2028 (US$ Million)
11.1.6.5.3 Spain: Glycomic Therapeutics Market, by Class, 2019-2028 (US$ Million)
11.1.6.5.4 Spain: Glycomic Therapeutics Market, by Structure, 2019-2028 (US$ Million)
11.1.6.5.4.1 Spain: Glycomic Therapeutics Market, by Targeting Glycosphingolipid, 2019-2028 (US$ Million)
11.1.6.5.4.2 Spain: Glycomic Therapeutics Market, by Targeting Sialic Acid, 2019-2028 (US$ Million)
11.1.6.5.4.3 Spain: Glycomic Therapeutics Market, by Targeting Glycosaminoglycans, 2019-2028 (US$ Million)
11.1.6.5.4.4 Spain: Glycomic Therapeutics Market, by Others, 2019-2028 (US$ Million)
11.1.6.5.5 Spain: Glycomic Therapeutics Market, by Indication, 2019-2028 (US$ Million)
11.1.6.5.6 Spain: Glycomic Therapeutics Market, by Mode of Action, 2019-2028 (US$ Million)
11.1.6.6 Rest of Europe: Glycomic Therapeutics Market – Revenue and Forecast to 2028 (US$ Million)
11.1.6.6.1 Overview
11.1.6.6.2 Rest of Europe: Glycomic Therapeutics Market – Revenue and Forecast to 2028 (US$ Million)
11.1.6.6.3 Rest of Europe: Glycomic Therapeutics Market, by Class, 2019-2028 (US$ Million)
11.1.6.6.4 Rest of Europe: Glycomic Therapeutics Market, by Structure, 2019-2028 (US$ Million)
11.1.6.6.4.1 Rest of Europe: Glycomic Therapeutics Market, by Targeting Sialic Acid, 2019-2028 (US$ Million)
11.1.6.6.4.2 Rest of Europe: Glycomic Therapeutics Market, by Targeting Glycosaminoglycan, 2019-2028 (US$ Million)
11.1.6.6.4.3 Rest of Europe: Glycomic Therapeutics Market, by Targeting Glycosphingolipids, 2019-2028 (US$ Million)
11.1.6.6.4.4 Rest of Europe: Glycomic Therapeutics Market, by Others, 2019-2028 (US$ Million)
11.1.6.6.5 Rest of Europe: Glycomic Therapeutics Market, by Indication, 2019-2028 (US$ Million)
11.1.6.6.6 Rest of Europe: Glycomic Therapeutics Market, by Mode of Action, 2019-2028 (US$ Million)
12. Glycomic Therapeutics Market –Industry Landscape
12.1 Overview
12.2 Growth Strategies in the Glycomic Therapeutics Market (%)
12.3 Organic Developments
12.3.1 Overview
12.4 Inorganic Developments
12.4.1 Overview
13. Company Profiles
13.1 Intellihep Ltd
13.1.1 Key Facts
13.1.2 Business Description
13.1.3 Products and Services
13.1.4 Financial Overview
13.1.5 SWOT Analysis
13.1.6 Key Developments
13.2 BioMarin Pharmaceutical Inc.
13.2.1 Key Facts
13.2.2 Business Description
13.2.3 Products and Services
13.2.4 Financial Overview
13.2.5 SWOT Analysis
13.2.6 Key Developments
13.3 Genzyme Corporation (Sanofi)
13.3.1 Key Facts
13.3.2 Business Description
13.3.3 Products and Services
13.3.4 Financial Overview
13.3.5 SWOT Analysis
13.3.6 Key Developments
13.4 Bayer AG
13.4.1 Key Facts
13.4.2 Business Description
13.4.3 Products and Services
13.4.4 Financial Overview
13.4.5 SWOT Analysis
13.4.6 Key Developments
13.5 GlycoMar
13.5.1 Key Facts
13.5.2 Business Description
13.5.3 Products and Services
13.5.4 Financial Overview
13.5.5 SWOT Analysis
13.5.6 Key Developments
13.6 GlaxoSmithKline plc.
13.6.1 Key Facts
13.6.2 Business Description
13.6.3 Products and Services
13.6.4 Financial Overview
13.6.5 SWOT Analysis
13.6.6 Key Developments
13.7 F. Hoffmann-La Roche Ltd
13.7.1 Key Facts
13.7.2 Business Description
13.7.3 Products and Services
13.7.4 Financial Overview
13.7.5 SWOT Analysis
13.7.6 Key Developments
14. Appendix
14.1 About The Insight Partners
14.2 Glossary of Terms in Glycomic Therapeutics Market

LIST OF TABLES

Table 1. Europe Glycomic Therapeutics Market, by C lass – Revenue and Forecast to 2028 (US$ Million)
Table 2. Europe Glycomic Therapeutics Market, by Indication – Revenue and Forecast to 2028 (USD Million)
Table 3. Europe Glycomic Therapeutics Market, by Structure – Revenue and Forecast to 2028 (USD Million)
Table 4. Europe Glycomic Therapeutics Market, by Targeting Sialic Acid – Revenue and Forecast to 2028 (USD Million)
Table 5. Europe Glycomic Therapeutics Market, by Targeting Glycosaminoglycan – Revenue and Forecast to 2028 (USD Million)
Table 6. Europe Glycomic Therapeutics Market, by Targeting Glycosphingolipids – Revenue and Forecast to 2028 (USD Million)
Table 7. Europe Glycomic Therapeutics Market, by Others– Revenue and Forecast to 2028 (USD Million)
Table 8. Europe Glycomic Therapeutics Market, by Mode of Action – Revenue and Forecast to 2028 (USD Million)
Table 9. Europe Glycomic Therapeutics Market, by C lass – Revenue and Forecast to 2028 (US$ Million)
Table 10. Europe Glycomic Therapeutics Market, by Structure – Revenue and Forecast to 2028 (USD Million)
Table 11. Europe Glycomic Therapeutics Market, by Targeting Sialic Acid – Revenue and Forecast to 2028 (USD Million)
Table 12. Europe Glycomic Therapeutics Market, by Targeting Glycosaminoglycan – Revenue and Forecast to 2028 (USD Million)
Table 13. Europe Glycomic Therapeutics Market, by Targeting Glycosphingolipids – Revenue and Forecast to 2028 (USD Million)
Table 14. Europe Glycomic Therapeutics Market, by Others– Revenue and Forecast to 2028 (USD Million)
Table 15. Europe Glycomic Therapeutics Market, by Indication – Revenue and Forecast to 2028 (USD Million)
Table 16. Europe Glycomic Therapeutics Market, by Mode of Action – Revenue and Forecast to 2028 (USD Million)
Table 17. Germany Glycomic Therapeutics Market, by Class – Revenue and Forecast to 2028 (US$ Million)
Table 18. Germany Glycomic Therapeutics Market, by Structure – Revenue and Forecast to 2028 (US$ Million)
Table 19. Germany Glycomic Therapeutics Market, by Targeting Sialic Acid – Revenue and Forecast to 2028 (US$ Million)
Table 20. Germany Glycomic Therapeutics Market, by Targeting Glycosaminoglycan – Revenue and Forecast to 2028 (US$ Million)
Table 21. Germany Glycomic Therapeutics Market, by Targeting Glycosphingolipids – Revenue and Forecast to 2028 (US$ Million)
Table 22. Germany Glycomic Therapeutics Market, by Others – Revenue and Forecast to 2028 (US$ Million)
Table 23. Germany Glycomic Therapeutics Market, by Indication – Revenue and Forecast to 2028 (US$ Million)
Table 24. Germany Glycomic Therapeutics Market, by Mode of Action – Revenue and Forecast to 2028 (US$ Million)
Table 25. UK Glycomic Therapeutics Market, by Class – Revenue and Forecast to 2028 (US$ Million)
Table 26. UK Glycomic Therapeutics Market, by Structure – Revenue and Forecast to 2028 (US$ Million)
Table 27. UK Glycomic Therapeutics Market, by Targeting Sialic Acid – Revenue and Forecast to 2028 (US$ Million)
Table 28. UK Glycomic Therapeutics Market, by Targeting Glycosaminoglycan – Revenue and Forecast to 2028 (US$ Million)
Table 29. UK Glycomic Therapeutics Market, by Targeting Glycosphingolipids – Revenue and Forecast to 2028 (US$ Million)
Table 30. UK Glycomic Therapeutics Market, by Others – Revenue and Forecast to 2028 (US$ Million)
Table 31. UK Glycomic Therapeutics Market, by Indication – Revenue and Forecast to 2028 (US$ Million)
Table 32. UK Glycomic Therapeutics Market, by Mode of Action – Revenue and Forecast to 2028 (US$ Million)
Table 33. France Glycomic Therapeutics Market, by Class – Revenue and Forecast to 2028 (US$ Million)
Table 34. France Glycomic Therapeutics Market, by Structure – Revenue and Forecast to 2028 (US$ Million)
Table 35. France Glycomic Therapeutics Market, by Targeting Sialic Acid – Revenue and Forecast to 2028 (US$ Million)
Table 36. France Glycomic Therapeutics Market, by Targeting Glycosaminoglycan – Revenue and Forecast to 2028 (US$ Million)
Table 37. France Glycomic Therapeutics Market, by Targeting Glycosphingolipids – Revenue and Forecast to 2028 (US$ Million)
Table 38. France Glycomic Therapeutics Market, by Others – Revenue and Forecast to 2028 (US$ Million)
Table 39. France Glycomic Therapeutics Market, by Indication – Revenue and Forecast to 2028 (US$ Million)
Table 40. France Glycomic Therapeutics Market, by Mode of Action – Revenue and Forecast to 2028 (US$ Million)
Table 41. Italy Glycomic Therapeutics Market, by Class – Revenue and Forecast to 2028 (US$ Million)
Table 42. Italy Glycomic Therapeutics Market, by Structure – Revenue and Forecast to 2028 (US$ Million)
Table 43. Italy Glycomic Therapeutics Market, by Targeting Sialic Acid – Revenue and Forecast to 2028 (US$ Million)
Table 44. Italy Glycomic Therapeutics Market, by Targeting Glycosaminoglycan – Revenue and Forecast to 2028 (US$ Million)
Table 45. Italy Glycomic Therapeutics Market, by Targeting Glycosphingolipids – Revenue and Forecast to 2028 (US$ Million)
Table 46. Italy Glycomic Therapeutics Market, by Others – Revenue and Forecast to 2028 (US$ Million)
Table 47. Italy Glycomic Therapeutics Market, by Indication – Revenue and Forecast to 2028 (US$ Million)
Table 48. Italy Glycomic Therapeutics Market, by Mode of Action – Revenue and Forecast to 2028 (US$ Million)
Table 49. Spain Glycomic Therapeutics Market, by Class – Revenue and Forecast to 2028 (US$ Million)
Table 50. Spain Glycomic Therapeutics Market, by Structure – Revenue and Forecast to 2028 (US$ Million)
Table 51. Spain Glycomic Therapeutics Market, by Targeting Glycosphingolipid – Revenue and Forecast to 2028 (US$ Million)
Table 52. Spain Glycomic Therapeutics Market, by Targeting Sialic Acid – Revenue and Forecast to 2028 (US$ Million)
Table 53. Spain Glycomic Therapeutics Market, by Targeting Glycosaminoglycans – Revenue and Forecast to 2028 (US$ Million)
Table 54. Spain Glycomic Therapeutics Market, by Others – Revenue and Forecast to 2028 (US$ Million)
Table 55. Spain Glycomic Therapeutics Market, by Indication – Revenue and Forecast to 2028 (US$ Million)
Table 56. Spain Glycomic Therapeutics Market, by Mode of Action – Revenue and Forecast to 2028 (US$ Million)
Table 57. Rest of Europe Glycomic Therapeutics Market, by Class – Revenue and Forecast to 2028 (US$ Million)
Table 58. Rest of Europe Glycomic Therapeutics Market, by Structure – Revenue and Forecast to 2028 (US$ Million)
Table 59. Rest of Europe Glycomic Therapeutics Market, by Targeting Sialic Acid – Revenue and Forecast to 2028 (US$ Million)
Table 60. Rest of Europe Glycomic Therapeutics Market, by Targeting Glycosaminoglycan – Revenue and Forecast to 2028 (US$ Million)
Table 61. Rest of Europe Glycomic Therapeutics Market, by Targeting Glycosphingolipids – Revenue and Forecast to 2028 (US$ Million)
Table 62. Rest of Europe Glycomic Therapeutics Market, by Others – Revenue and Forecast to 2028 (US$ Million)
Table 63. Rest of Europe Glycomic Therapeutics Market, by Indication – Revenue and Forecast to 2028 (US$ Million)
Table 64. Rest of Europe Glycomic Therapeutics Market, by Mode of Action – Revenue and Forecast to 2028 (US$ Million)
Table 65. Organic Developments in the Glycomic Therapeutics Market
Table 66. Inorganic Developments in the Glycomic Therapeutics Market
Table 67. Glossary of Terms in Glycomic Therapeutics Market

LIST OF FIGURES

Figure 1. Europe Glycomic Therapeutics Market Segmentation
Figure 2. Europe Glycomic Therapeutics Market, By Country
Figure 3. Europe Glycomic Therapeutics Market Overview
Figure 4. Synthetic Segment Held Largest Share of Class Segment in Europe Glycomic Therapeutics Market
Figure 5. Asia Pacific is Expected to Show Remarkable Growth During the Forecast Period
Figure 6. Europe: PEST Analysis
Figure 7. Europe Glycomic Therapeutics Market Impact Analysis of Driver and Restraints
Figure 8. Europe Glycomics market – Revenue Forecast And Analysis – 2020- 2028
Figure 9. Europe Glycomic Therapeutics Market, by Class 2022 & 2028 (%)
Figure 10. Europe Isolated Revenue and Forecasts to 2028 (US$ Million)
Figure 11. Europe Synthetic – Revenue and Forecasts to 2028 (US$ Million)
Figure 12. Europe Glycomics Market, by Indication 2022 & 2028 (%)
Figure 13. Europe Thrombosis and chemoprophylaxis Revenue and Forecasts to 2028 (US$ Million)
Figure 14. Europe Anaemia Revenue and Forecasts to 2028 (US$ Million)
Figure 15. Europe Anti-adhesive and Anti-inflammatory Revenue and Forecasts to 2028 (US$ Million)
Figure 16. Europe Cataract Revenue and Forecasts to 2028 (US$ Million)
Figure 17. Europe Gaucher’s diseases Revenue and Forecasts to 2028 (US$ Million)
Figure 18. Europe MPS-1 & IV Revenue and Forecasts to 2028 (US$ Million)
Figure 19. Europe Cancer Revenue and Forecasts to 2028 (US$ Million)
Figure 20. Europe Alzheimer’s Revenue and Forecasts to 2028 (US$ Million)
Figure 21. Europe Influenza Type A and B Revenue and Forecasts to 2028 (US$ Million)
Figure 22. Europe Others Revenue and Forecasts to 2028 (US$ Million)
Figure 23. Europe Glycomic Therapeutics Market, by Structures 2022 & 2028 (%)
Figure 24. Europe Glycoproteins – Market Revenue and Forecasts to 2028 (US$ Million)
Figure 25. Europe Targeting Sialic Acid – Market Revenue and Forecasts to 2028 (US$ Million)
Figure 26. Europe Zanamivir – Market Revenue and Forecasts to 2028 (US$ Million)
Figure 27. Europe Oseltamivir – Market Revenue and Forecasts to 2028 (US$ Million)
Figure 28. Europe Proteoglycans – Market Revenue and Forecasts to 2028 (US$ Million)
Figure 29. Europe Glycosylphosphatidylinositol (GPI)-Anchored Proteins and Heparin Based Glycans – Market Revenue and Forecasts to 2028 (US$ Million)
Figure 30. Europe Targeting Glycosaminoglycans – Market Revenue and Forecasts to 2028 (US$ Million)
Figure 31. Europe Heparin – Market Revenue and Forecasts to 2028 (US$ Million)
Figure 32. Europe Hyaluronan (HA) – Market Revenue and Forecasts to 2028 (US$ Million)
Figure 33. Europe Laronidase – Market Revenue and Forecasts to 2028 (US$ Million)
Figure 34. Europe Galsulfase (Naglazyme) – Market Revenue and Forecasts to 2028 (US$ Million)
Figure 35. Europe Hyaluronidase (Cumulase) – Market Revenue and Forecasts to 2028 (US$ Million)
Figure 36. Europe Others – Market Revenue and Forecasts to 2028 (US$ Million)
Figure 37. Europe Targeting Glycosphingolipids – Market Revenue and Forecasts to 2028 (US$ Million)
Figure 38. Europe Imiglucerase (Cerezyme – Market Revenue and Forecasts to 2028 (US$ Million)
Figure 39. Europe Agalsidase (Fabrazyme) – Market Revenue and Forecasts to 2028 (US$ Million)
Figure 40. Europe N-butyl-deoxynojirimycin (DNJ) – Market Revenue and Forecasts to 2028 (US$ Million)
Figure 41. Europe Others – Market Revenue and Forecasts to 2028 (US$ Million)
Figure 42. Europe Others – Market Revenue and Forecasts to 2028 (US$ Million)
Figure 43. Europe Acarbose – Market Revenue and Forecasts to 2028 (US$ Million)
Figure 44. Europe Alglucosidase Alfa (Myozyme) – Market Revenue and Forecasts to 2028 (US$ Million)
Figure 45. Europe Allosamidin – Market Revenue and Forecasts to 2028 (US$ Million)
Figure 46. Europe Others – Market Revenue and Forecasts to 2028 (US$ Million)
Figure 47. Europe Glycomic Therapeutics Market, by Mode of Action 2022 & 2028 (%)
Figure 48. Europe Inhibits Neuraminidase – Market Revenue and Forecasts to 2028 (US$ Million)
Figure 49. Europe Inhibits Heparanase And Selectins And Blocks Interactions Between Growth Factors And Heparan Sulfate – Market Revenue and Forecasts to 2028 (US$ Million)
Figure 50. Europe Erythropoietin And Enzyme Replacement Therapy (ERT) – Market Revenue and Forecasts to 2028 (US$ Million)
Figure 51. Europe Tissue Plasminogen Activator – Market Revenue And Forecasts To 2028 (US$ Million)
Figure 52. Europe Inhibits Glucosylceramide Synthase – Market Revenue And Forecasts To 2028 (US$ Million)
Figure 53. Europe Interleukin 1 And 2 And 3- Market Revenue And Forecasts To 2028 (US$ Million)
Figure 54. Europe Beta And Gamma Interferons – Market Revenue And Forecasts To 2028 (US$ Million)
Figure 55. Europe Others – Market Revenue And Forecasts To 2028 (US$ Million)
Figure 56. Europe: Glycomic Therapeutics Market, by Key Country – Revenue (2022) (US$ Million)
Figure 57. Europe: Glycomic Therapeutics Market, by Country, 2021 & 2028 (%)
Figure 58. Germany: Glycomic Therapeutics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 59. UK: Glycomic Therapeutics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 60. France: Glycomic Therapeutics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 61. Italy: Glycomic Therapeutics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 62. Spain: Glycomic Therapeutics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 63. Rest of Europe: Glycomic Therapeutics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 64. Growth Strategies in the Glycomic Therapeutics Market (%)

● Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Europe Glycomic Therapeutics Market.
● Highlights key business priorities in order to assist companies to realign their business strategies.
● The key findings and recommendations highlight crucial progressive industry trends in Europe Glycomic Therapeutics Market, thereby allowing players across the value chain to develop effective long-term strategies.
● Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
● Scrutinize in-depth Europe market trends and outlook coupled with the factors driving the market, as well as those hindering it.
● Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.

The List of Companies – Europe Glycomic Therapeutics Market

● Intellihep Ltd                                                      
● BioMarin Pharmaceutical Inc.                    
● Genzyme Corporation (Sanofi)                 
● Bayer AG                                                            
● GlycoMar                                                           
● GlaxoSmithKline plc.           
● F. Hoffmann-La Roche Ltd                           

Pricing

$3,000.00$5,000.00

Have a Query?

Have a Question?

Sample PDF showcases the content structure and the nature of the information included in the report which presents a qualitative and quantitative analysis.

GET FREE SAMPLE PDF

× Enquire Now